Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill (VASTVALUS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01073800|
Recruitment Status : Completed
First Posted : February 23, 2010
Last Update Posted : December 16, 2011
Patients are admitted to the critical care unit of the hospital because of medical conditions that have a high likelihood of causing severe problems with blood flow, breathing, or brain function. These conditions also have a high likelihood of causing death. Approximately 10 to 15% of all critically ill patients die in hospital. A large amount of scientific evidence suggests that a substantial proportion of these deaths is due to a combination of blot clotting and inflammation in the blood vessels.
Statins are drugs that interfere with cholesterol and fat metabolism. Cholesterol and fat in the blood are associated with blood clotting and inflammation in the blood vessels. Statins are known to be very beneficial in improving the survival after heart attacks, and in preventing heart attacks.
The question that VASTVALUS asks is: do statins improve survival among all critically ill patients? In VASTVALUS, we will concentrate on patients that do not currently require a statin because of their medical condition e.g. after a heart attack, but we are concerned with the rest of the critically ill. In VASTVALUS, participating patients will receive either atorvastatin 80 mg daily or a placebo. Atorvastatin is a statin with a well-established record of safety and effectiveness. A placebo has no known medical activity. We will follow all patients in VASTVALUS to determine whether atorvastatin has any effect on the occurrence of death, stroke, heart attack, or kidney failure among the critically ill. Results from VASTVALUS will be shared with the medical community after the study is completed. As with all clinical trials, patients in VASTVALUS participate of their own choice, and can change their mind at any time.
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Infarction Stroke Renal Failure||Drug: atorvastatin 80 mg per os daily Drug: placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill|
|Study Start Date :||April 2009|
|Actual Primary Completion Date :||August 2009|
|Actual Study Completion Date :||September 2011|
Active Comparator: atorvastatin 80 mg
Drug: atorvastatin 80 mg per os daily
atorvastatin 80 mg per os daily
|Placebo Comparator: placebo||
- vascular occlusive events [ Time Frame: 30 days ]
- liver enzyme elevation [ Time Frame: 30 days ]
- rhabdomyolysis [ Time Frame: 30 days ]
- myalgias [ Time Frame: 30 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01073800
|University of Alberta|
|Edmonton, Alberta, Canada, T6G 2B7|